Aerie Pharmaceuticals Inc. (AERI) Major Shareholder Sells $2,017,000.00 in Stock
Aerie Pharmaceuticals Inc. (NASDAQ:AERI) major shareholder Foresite Capital Fund Ii, L.P. sold 50,000 shares of the business’s stock in a transaction on Thursday, October 6th. The stock was sold at an average price of $40.34, for a total transaction of $2,017,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Foresite Capital Fund Ii, L.P. also recently made the following trade(s):
- On Friday, July 22nd, Foresite Capital Fund Ii, L.P. purchased 250,000 shares of Aerie Pharmaceuticals stock. The stock was bought at an average price of $17.50 per share, for a total transaction of $4,375,000.00.
Shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) opened at 40.49 on Friday. The stock’s market capitalization is $1.13 billion. The company has a 50-day moving average of $28.57 and a 200-day moving average of $19.49. Aerie Pharmaceuticals Inc. has a 52-week low of $10.82 and a 52-week high of $41.72.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/08/aerie-pharmaceuticals-inc-aeri-major-shareholder-sells-2017000-00-in-stock.html
Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.02. Equities research analysts anticipate that Aerie Pharmaceuticals Inc. will post ($2.81) EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Mercantile Trust Co. purchased a new position in Aerie Pharmaceuticals during the third quarter worth $161,000. Barclays PLC boosted its position in Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock worth $106,000 after buying an additional 200 shares during the last quarter. BlackRock Advisors LLC boosted its position in Aerie Pharmaceuticals by 15.0% in the second quarter. BlackRock Advisors LLC now owns 12,310 shares of the company’s stock worth $217,000 after buying an additional 1,608 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Aerie Pharmaceuticals during the second quarter worth $219,000. Finally, American International Group Inc. boosted its position in Aerie Pharmaceuticals by 8.5% in the second quarter. American International Group Inc. now owns 13,864 shares of the company’s stock worth $244,000 after buying an additional 1,082 shares during the last quarter. 95.22% of the stock is owned by institutional investors.
AERI has been the topic of several research analyst reports. Canaccord Genuity set a $50.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, September 14th. Brean Capital set a $48.00 price target on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, September 15th. Stifel Nicolaus boosted their price target on shares of Aerie Pharmaceuticals from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 15th. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 price target (up previously from $45.00) on shares of Aerie Pharmaceuticals in a research note on Thursday, September 15th. Finally, Cantor Fitzgerald boosted their price target on shares of Aerie Pharmaceuticals from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 15th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and an average target price of $51.40.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.